# Tempest Therapeutics, Inc.: Form 10-Q for the period ended Mar 31, 2015

- Company: [Tempest Therapeutics, Inc.](/companies/tpst.md) (CIK 1544227)
- Form: 10-Q
- Filed: 2015-05-11
- Accepted by EDGAR: May 11, 2015, 16:12 ET
- Period: 2015-03-31
- Accession: 0001104659-15-036822
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1544227/000110465915036822/a15-7301_110q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1544227/000110465915036822/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-01-01 to 2015-03-31 | $15.0k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2015-01-01 to 2015-03-31 | $35.0k | us-gaap:CostOfRevenue |
| Research and development | 3 months, 2015-01-01 to 2015-03-31 | $5.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2015-01-01 to 2015-03-31 | $11.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2015-01-01 to 2015-03-31 | −$16.8m | us-gaap:OperatingIncomeLoss |
| Net income | 3 months, 2015-01-01 to 2015-03-31 | −$17.2m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-01-01 to 2015-03-31 | −$0.65 | us-gaap:EarningsPerShareBasicAndDiluted |
| Capital expenditure | 3 months, 2015-01-01 to 2015-03-31 | $389.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2015-03-31 | $134.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-03-31 | $171.3m | us-gaap:AssetsCurrent |
| Total assets | at 2015-03-31 | $175.8m | us-gaap:Assets |
| Current liabilities | at 2015-03-31 | $6.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-03-31 | $6.7m | us-gaap:Liabilities |
| Shareholders' equity | at 2015-03-31 | $169.1m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 25,915 characters.

*This Quarterly Report on Form 10-Q contains forward-looking statements that involve risks and uncertainties. The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Without limiting the foregoing, the words “may,” “shall,” “will,” “should,” “could,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” “target,” “goal”, “seek”, “likely,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. All forward-looking statements included in this Quarterly Report on Form 10-Q are based on information available to us up to, and including, the date of this document, and we expressly disclaim any obligation to update any such forward-looking statements to reflect events or circumstances that arise after the date hereof. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain important factors, including those set forth in this Item 2 — “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” as well as under the heading “Risk Factors” contained in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2014 and elsewhere in this Quarterly Report on Form 10-Q. You should carefully review those factors and also carefully review the risks outlined in other documents that we file from time to time with the Securities and Exchange Commission, or SEC.*

### Overview

OvaScience is a global fertility company focused on the discovery, development, and commercialization of new treatment options. More women around the world are waiting to start families. However, fertility decreases with age. A major cause of infertility, especially in older women, is poor egg health, which is linked to a reduction in the number of functioning mitochondria. Accordingly, women throughout the world are increasingly seeking new treatment options for infertility. The current standard of treatment for infertility is *in vitro* fertilization, or IVF, but it fails approximately 70% of the time.

Our patented technology is based on egg precursor, or EggPCSM, cells, which are immature egg cells found in the protective outer lining of a woman’s own ovaries. These immature egg cells have the ability to grow into fresh, young, healthy eggs. The discovery of EggPC cells countered a long-held medical belief that women are born with a set number of eggs, thereby enabling new fertility treatment options.

Our portfolio of fertility treatment options uses proprietary methods to identify and isolate EggPC cells from a woman’s ovarian tissue. By applying our EggPC technology platform in unique ways, we are developing and commercializing new fertility treatment options that are designed to improve egg health and revolutionize IVF.

Our first treatment, the AUGMENTSM treatment, has been launched in select international IVF clinics, and we anticipate that we will introduce the AUGMENT treatment into new international regions in 2015. The AUGMENT treatment is not available in the United States. This treatment is specifically designed to improve egg health by supplementing a mitochondrial deficiency and may, in turn, improve IVF. With the AUGMENT treatment, energy-producing mitochondria from a woman’s own EggPC cells are added to the woman’s mature eggs during the IVF process to supplement the existing mitochondria. We expect 1,000 AUGMENT treatment cycles will be in process by the end of 2015. We have set this target to ensure that we are building a high-quality and scalable operating process to support our future fertility treatment portfolio.

The OvaPrimeSM treatment is a potential fertility treatment that could enable a woman to increase her egg reserve. The OvaPrime treatment is designed to replenish a woman’s egg reserve by transferring a patient’s EggPC cells from the protective ovarian lining back into the patient’s own ovaries where they may mature into fertilizable eggs during the IVF process. We reported large animal proof-of-concept studies in 2014 and plan to optimize the process and introduce the OvaPrime treatment to patients in at least one international region outside of the United States by the end of 2015.

The OvaTureSM treatment is a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without the need for hormone injections. The OvaTure treatment seeks to mature a woman’s own EggPC cells into eggs outside her body. This potential treatment may be an option for women with compromised eggs, who are unable to make eggs, or who may be unwilling or unable to undergo hormone hyperstimulation, such as women diagnosed with cancer. We established human preclinical proof-of-concept in 2014 by demonstrating that human EggPC cells can be matured into eggs outside of the body, and we plan to optimize the process and define the development pathway for the OvaTure treatment in 2015.

We believe our EggPC technology has the potential to make significant advances in the field of fertility because it is designed to address poor egg health and embryo quality due to age and other causes. We believe our EggPC technology could improve IVF by:

*Increasing live birth rates and reducing the number of IVF cycles.* By improving egg health, we believe we may increase the percentage of live births and reduce the number of IVF cycles required.

*Reducing the incidence of multiple births.* By generating higher quality eggs, we believe our EggPC technology may allow for the transfer of fewer embryos per IVF cycle and, as a result, lower the incidence of multiple births and the associated complications.

*Lowering the overall cost of the IVF process.* If we reduce the number of IVF cycles required for a live birth and the incidence of multiple births, we believe our fertility treatment options may also lower the overall costs associated with the IVF process.

*Replenishing the ovary for women who make too few or no eggs.* Our OvaPrime treatment is designed to replenish a woman’s egg reserve by transferring a patient’s EggPC cells from the protective ovarian lining back into the patient’s own ovaries where they may mature into fertilizable eggs during the IVF process.

*Reducing the need for hormonal hyperstimulation.* We are designing our OvaTure treatment to mature EggPC cells into fertilizable eggs *in vitro,* or outside the body. If successful, the OvaTure treatment could reduce, or possibly eliminate, the need for hormonal hyperstimulation for the maturation of multiple oocytes prior to egg retrieval in the IVF process.

*Preventing inherited diseases.* OvaXonSM is a joint venture with Intrexon Corporation, or Intrexon, which is focused on developing new applications to prevent the transmission of inherited diseases using our EggPC cells technology and Intrexon’s synthetic biology and high throughput platform for applications in human and animal health.

### The AUGMENT Treatment

We have launched the AUGMENT treatment in select international IVF clinics and anticipate that we will introduce the AUGMENT treatment into new international regions in 2015. Initial positive clinical experiences with the AUGMENT treatment were presented in poster sessions at the Society for Reproductive Investigation (SRI) 62nd Annual Meeting in March 2015 by two IVF specialists who are offering the AUGMENT treatment in their practices, Robert F. Casper, M.D., F.R.C.S.(C), Medical Director of TCART Fertility Partners of Toronto, Canada, and Kutluk Oktay, M.D., F.A.C.O.G, of Gen-art IVF in Ankara, Turkey. Both doctors reported ongoing clinical pregnancies in women who had poor embryo development and failed to have a successful pregnancy after multiple IVF cycles and embryo transfers. The AUGMENT treatment is not available in the United States. As part of the AUGMENT treatment, a woman’s eggs may be revitalized by injecting mitochondria from her own EggPC cells into her egg during IVF. This has the potential to improve egg health and may, in turn, offer the potential for improved IVF.

The AUGMENT treatment complements the existing standard of practice for an IVF cycle. Prior to hormone hyperstimulation, a small ovarian tissue biopsy is taken by the patient’s doctor. Our proprietary process identifies and isolates the patient’s own EggPC cells, and then the patient’s own mitochondria from these EggPC cells are isolated. The patient’s own mitochondria are then injected into her egg at the time of intracytoplasmic sperm injection, or ICSI.

We expect 1,000 AUGMENT treatment cycles will be in process by the end of 2015. The AUGMENT treatment cycle begins upon our receipt of the patient’s tissue. We expect to receive payment before processing tissue and defer revenue until we deliver the mitochondria to the clinic.

We continue to target major international regions for the AUGMENT treatment that combine elements of the following key criteria:

- Key opinion leaders
- High volume IVF clinics
- High quality IVF labs
- Out-of-pocket pay and high average cost per cycle
- Donor egg restrictions

### Recent Developments

On April 29, 2015, our Board of Directors appointed John Sexton, Ph.D., the President of New York University (NYU), to our Board to serve as a Class II Director with a term expiring at the 2017 annual meeting of stockholders.

### Critical Accounting Policies and Significant Judgments and Estimates

The discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of our condensed consolidated financial statements requires us to make judgments, estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. We evaluate our estimates, on an ongoing basis, including those related to accrued expenses and assumptions in the valuation of stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable in the circumstances. Actual results could differ from those estimates.

Refer to Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Annual Report on Form 10-K for the year ended December 31, 2014 for a discussion of our critical accounting policies and estimates.

There were no significant changes to our critical accounting policies and estimates in the three months ended March 31, 2015.

We have irrevocably elected not to follow the extended transition period available to emerging growth companies provided for in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards.

### Results of Operations

The following table summarizes our results of operations for the three months ended March 31, 2015 and 2014, together with the change in these items in thousands of dollars and as a percentage (dollars in thousands):

|  | Three Months Ended, March 31, 2015 | 2014 | 2015 / 2014 Comparison Increase / (Decrease) $% |  |
| --- | ---: | ---: | ---: | ---: |
| Revenues | $15 | $— | $15 | 100% |
| Costs of revenues | 35 | — | 35 | 100% |
| Research and development expenses | 5,747 | 4,652 | 1,095 | 24% |
| Selling, general and administrative expenses | 11,046 | 2,998 | 8,048 | 268% |
| Interest income (expense), net | 44 | (57) | 101 | -177% |
| Other income (expense), net | 34 | (10) | 44 | -440% |
| Loss from equity method investment | 471 | 97 | 374 | 386% |
| Net Loss | $17,206 | $7,814 | $9,392 | 120% |

### Revenues

We commenced our first commercial AUGMENT treatment in December 2014 and recorded $15.0 thousand of treatment revenues in the first quarter of 2015 for that AUGMENT cycle. During the three months ended March 31, 2015, we continued to transition certain of our ACE clinics to commercial centers and, as anticipated, began performing limited commercial AUGMENT treatment cycles, for which we received cash and expect to recognize the associated revenue over the coming quarters. The AUGMENT treatment cycle begins upon our receipt of the patient’s tissue. We expect to receive payment before processing tissue and defer treatment revenues until we deliver the mitochondria to the clinic. Based on our experiences to date, the period from receipt of the patient’s tissue to recording revenue is expected to range between 30 and 120 days, the typical timeframe required to perform an IVF cycle. Accordingly, we do not expect to have significant revenue or deferred revenue until the second half of 2015, and we expect that a majority of this revenue and deferred revenue will be recorded in the fourth quarter. Our ability to generate revenue in the near-term will depend on the number of commercial AUGMENT treatment cycles our ACE clinics perform and the treatment prices charged. We expect that the commercial ramp of the AUGMENT treatment during 2015 will depend upon the successful transition of ACE clinics to commercial operations, the addition of new ACE clinics and the results from ACE clinic experience as they become available.

### Costs of Revenues

To provide our AUGMENT treatment we establish laboratories and hire scientific personnel to process the patient tissue. Therefore, we expect the cost of processing an AUGMENT treatment to decline as these fixed costs will be allocated over a larger number of treatments as we continue our commercial launch. Our costs of revenues include the cost of processing patient tissue that corresponds to treatment revenues for the reporting period. We recorded initial revenues related to the AUGMENT treatment and corresponding costs of revenues during the first quarter of 2015. We did not have costs of revenues in Q1 2014.

### Research and Development Expense

The $1.1 million, or 24%, increase in our research and development expense for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 was primarily attributable to:

- An increase of $2.2 million in stock-based compensation expense. The increase was primarily driven by certain mark-to-market adjustments of Founders’ stock for an additional $1.9 million.
- The additional costs were offset by a net $0.8 million decrease in license fees, resulting from a decrease of $1.0 million for the milestone that became due in 2014 upon completion of our public offering in 2014 and did not recur in 2015, which were offset by $0.2 million for a milestone incurred as a result of our first commercial AUGMENT treatment.

We expect research and development expense to increase if our programs successfully advance. We do not believe that the historical costs are indicative of the future costs associated with these programs nor do they represent what any other future treatment program we initiate may cost. Due to the variability in the length of time and scope of activities necessary to develop a fertility treatment and uncertainties related to cost estimates and our ability to commercialize and/or obtain marketing approval for our treatments, accurate and meaningful estimates of the total costs required to bring our treatments to market are not available.

Because of the risks inherent in discovery and development, we cannot reasonably estimate or know:

- The nature, timing and estimated costs of the efforts necessary to complete the development of our programs;
- The anticipated completion dates of these programs; or
- The period in which material net cash inflows are expected to commence, if at all, from the programs described above and any potential future treatments.

### Selling, General and Administrative Expense

Selling, general and administrative costs consist of ongoing costs to run our operations and continue to support the expanding international availability of the ACE access program for the AUGMENT treatment. The $8.0 million, or 268%, increase in selling, general and administrative expense for the three months ended March 31, 2015 as compared to the three months ended March 31, 2014 was primarily due to:

- An increase of $4.5 million for employee compensation and related benefits, including stock-based compensation expense. The increase was primarily driven by the hiring of new selling, general and administrative personnel and $1.1 million in stock-based compensation expense related to Founders’ stock requiring mark-to-market accounting treatment.
- An increase of $1.7 million in ACE access program set-up costs including travel and facilities costs.
- An increase of $1.4 million in additional consulting, legal and marketing expenses as we continue to focus on the expanding international availability of the AUGMENT treatment.
- An increase of $0.4 million in facilities and other administrative costs.

### Interest Income (Expense), Net

In the three months ended March 31, 2015 there was immaterial interest income, net related to short-term investments. Interest expense, net was $0.1 million for the three months ended March 31, 2014 which included $0.3 million of short term investment amortization and interest expense incurred to record the final installment payment due to Intrexon at fair value offset by $0.2 million of interest income.

### Loss from Equity Method Investment

Loss from equity method investment was $0.5 million and $0.1 million for the three months ended March 31, 2015 and 2014, respectively. The losses result from our OvaXon joint venture established in December 2013.

### Liquidity and Capital Resources

### Sources of Liquidity

We have generated limited AUGMENT treatment revenue to date. We have relied on the proceeds from sales of equity securities to fund our operations. Our short-term investments primarily trade in liquid markets, and the average days to maturity of our portfolio as of March 31, 2015 are less than six months. Because our fertility treatments are in various stages of development and the outcome of these efforts is uncertain, we cannot estimate the actual amounts necessary to successfully complete the development and commercialization of our treatments or whether or when we may achieve profitability.

Our significant capital resources are as follows (in thousands):

|  | March 31, 2015 | December 31, 2014 |
| --- | ---: | ---: |
| Cash, cash equivalents and short-term investments | $169,339 | $60,231 |
| Working capital | 164,725 | 51,704 |

| Cash (used in) provided by: | Three Months Ended, March 31, 2015 | 2014 |
| --- | ---: | ---: |
| Operating activities | $(14,394) | $(4,961) |
| Investing activities | 17,891 | (8,644) |
| Capital expenditures (included in investing activities above) | (389) | — |
| Financing activities | 124,787 | 51,661 |

### Cash Flows

Cash used in operating activities in both of the periods presented was primarily driven by our net loss. Cash flows from operations can vary significantly due to various factors, including changes in the net loss and the timing of disbursements made for accounts payable and accruals.

Cash used in investing activities for the three months ended March 31, 2015 included a $0.8 million investment in a joint venture and capital expenditures of $0.4 million, which were offset by $19.0 million of proceeds from maturities of short-term investments. Capital expenditures in the three months ended March 31, 2015 primarily consisted of laboratory equipment.

Cash used in investing activities for the three months ended March 31, 2014 included the purchase of and proceeds from maturities of short-term investments and $4.4 million in sales of short-term investments. Our investing activities for the three months ended March 31, 2014 included $1.5 million investment in a joint venture.

Net cash provided by financing activities for the three months ended March 31, 2015 was primarily the result of an underwritten public offering of an aggregate of 2,645,000 shares of common stock at a price per share of $50.00 resulting in net proceeds of $124.1 million. Stock option exercises and issuances of common stock resulted in net proceeds of $0.7 million.

Net cash provided by financing activities for the three months ended March 31, 2014 was primarily the result of a underwritten public offering of an aggregate of 5,518,630 shares of common stock at a price per share of $10.00 resulting in net proceeds of $51.7 million.

We may need substantial additional funds to support our planned operations and commercialization strategy. We expect our existing cash, cash equivalents and short-term investments of $169.3 million at March 31, 2015 will enable us to fund our current operating plan at least into 2017. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our treatments, and the extent to which we may enter into collaborations with third parties for development and commercialization of our treatments, we are unable to estimate the amounts of increased capital outlays and operating expenses associated with completing the development of our current treatments in development. Our future capital requirements will depend on many factors, including:

- our success in expanding to new ACE clinics in other major regions of the world, transitioning ACE clinics to commercial centers and significantly increasing the number of patients receiving the AUGMENT treatment;
- our success in optimizing and introducing the OvaPrime treatment to international IVF clinics;
- the costs associated with the expansion of foreign operations and building out our international commercial infrastructure, including establishing and staffing an international headquarters and other international subsidiaries;
- the costs associated with establishing a domestic and international sales, marketing, manufacturing and distribution infrastructure to commercialize the AUGMENT treatment and any potential fertility treatment we successfully develop;
- the pricing of the AUGMENT treatment and resulting revenues, as well as any future revenues we receive from our potential fertility treatments;
- the costs of continuing the optimization of the OvaTure treatment and our success in defining a development pathway;
- the costs of any clinical trials of potential fertility treatments;
- the costs involved in collaborating with Intrexon through the OvaXon joint venture to create new applications to prevent inherited diseases for human and animal health;
- following any applicable regulatory process in the United States and abroad, including the premarketing and marketing approval requirements, to which any of our potential fertility treatments may be subject;
- following any regulatory or institutional review board review of our potential fertility treatments that are subject to such review;
- preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;
- establishing collaborations and partnerships on favorable terms, if at all; and
- developing, acquiring or in-licensing other potential fertility treatments and technologies.

Until such time, if ever, as we can generate sufficient revenues from the AUGMENT treatment or our potential fertility treatments to become profitable, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and licensing arrangements. We do not have any committed external source of funds. In addition, we may elect to raise additional funds even before we need them if the conditions for raising capital are favorable. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or treatments or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our fertility treatment development or future commercialization efforts or grant rights to develop and market treatments that we would otherwise prefer to develop and market ourselves.

### Off-Balance Sheet Arrangements

We did not have during the periods presented, and we do not currently have, any off-balance sheet arrangements, as defined under SEC rules.

### Contractual Obligations

There have been no material changes to our contractual obligations set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Contractual Obligations” in our Annual Report on Form 10-K for the year ended December 31, 2014.

### Recently Adopted Accounting Standards

There are no recently issued accounting standards that have a material impact on us for the periods presented.

## Market risk

As filed, 1,015 characters.

Our interest income is sensitive to changes in the general level of U.S. interest rates, particularly since a significant portion of our investments are in money market funds and corporate obligations. We do not enter into investments for trading or speculative purposes. We maintain our cash, cash equivalents and short-term investments with a high quality, accredited financial institution. Our marketable securities are subject to interest rate risk and will fall in value if market interest rates increase.

A hypothetical 100 basis point increase in interest rates would result in an approximately $0.1 million decrease in the fair value of our investments as of March 31, 2015, as compared to an approximately $0.2 million decrease as of December 31, 2014. We have the ability to hold our fixed income investments until maturity and, therefore, we do not expect our operating results or cash flows to be affected to any significant degree by the effect of a change in market interest rates on our investments.

## Controls and procedures

As filed, 1,939 characters.

*Evaluation of Disclosure Controls and Procedures.* Our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2015. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of March 31, 2015, our principal executive officer and principal financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

*Changes in Internal Controls.* No change in our internal control over financial reporting occurred during the fiscal quarter ended March 31, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

## Risk factors

As filed, 550 characters.

You should carefully review and consider the information regarding certain factors that could materially affect our business, financial condition or future results set forth under Item 1A. (Risk Factors) in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014. There have been no material changes from the factors disclosed in our 2014 Annual Report on Form 10-K, although we may disclose changes to such factors or disclose additional factors from time to time in our future filings with the Securities and Exchange Commission.

Filed May 11, 2015.
Source: SEC EDGAR, the filing index for accession 0001104659-15-036822. Last ingested by Listed: Nov 15, 2026, 00:20 ET. No prices; not investment advice.
